Später Thomas, Worringer Denise Ms, Menger Maximilian M, Menger Michael D, Laschke Matthias W
Institute for Clinical & Experimental Surgery, Saarland University, Homburg/Saar, Germany.
Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tuebingen, BG Trauma Center Tuebingen, Tuebingen, Germany.
J Tissue Eng. 2021 Mar 16;12:20417314211000304. doi: 10.1177/20417314211000304. eCollection 2021 Jan-Dec.
Adipose tissue-derived microvascular fragments (MVF) are used as vascularization units in tissue engineering. In this study, we investigated whether the vascularization capacity of MVF can be improved by systemic low-dose erythropoietin (EPO) administration. MVF were isolated from the epididymal fat of donor mice and seeded onto collagen-glycosaminoglycan matrices, which were implanted into full-thickness skin defects within dorsal skinfold chambers of recipient mice. Both donor and recipient mice were treated daily with either EPO (500 IU/kg) or vehicle (0.9% NaCl). The implants were analyzed by stereomicroscopy, intravital fluorescence microscopy, histology, and immunohistochemistry. EPO-treated MVF contained a comparable number of proliferating Ki67 but less apoptotic cleaved caspase-3 endothelial cells when compared to vehicle-treated controls. Moreover, EPO treatment accelerated and improved the in vivo vascularization, blood vessel maturation, and epithelialization of MVF-seeded matrices. These findings indicate that systemic low-dose EPO treatment is suitable to enhance the viability and network-forming capacity of MVF.
脂肪组织来源的微血管片段(MVF)在组织工程中用作血管化单元。在本研究中,我们调查了全身性低剂量促红细胞生成素(EPO)给药是否能提高MVF的血管化能力。从供体小鼠的附睾脂肪中分离出MVF,并接种到胶原-糖胺聚糖基质上,然后将其植入受体小鼠背部皮褶腔的全层皮肤缺损处。供体和受体小鼠均每日接受EPO(500 IU/kg)或载体(0.9% NaCl)治疗。通过体视显微镜、活体荧光显微镜、组织学和免疫组织化学对植入物进行分析。与载体处理的对照组相比,EPO处理的MVF含有相当数量的增殖性Ki67,但凋亡的裂解型半胱天冬酶-3内皮细胞较少。此外,EPO处理加速并改善了MVF接种基质的体内血管化、血管成熟和上皮化。这些发现表明,全身性低剂量EPO治疗适合增强MVF的活力和网络形成能力。